^
Association details:
| Biomarker: | VHL mutation |
|---|---|
| Cancer: | Clear Cell Renal Cell Carcinoma |
| Drug Class: | VEGFR inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
VHL and DNA damage repair pathway alterations as potential clinical biomarkers for first-line TKIs in metastatic clear cell renal cell carcinomas
Excerpt:
A retrospective study of 56 patients with mccRCC who received first-line VEGFR-TKIs and who underwent genomic profiling and whole transcriptome sequencing was conducted....We found that patients with mccRCC harboring DDR and VHL alterations were more likely to benefit from first-line VEGF-TKI systemic therapy than patients with wild-type disease.
DOI:
10.1007/s13402-022-00691-8
